Enteropathy-Associated T cell Lymphoma.
Celiac disease
EATL
Intestinal lymphoma
T cell Lymphoma
Journal
Current hematologic malignancy reports
ISSN: 1558-822X
Titre abrégé: Curr Hematol Malig Rep
Pays: United States
ID NLM: 101262565
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
accepted:
12
04
2021
pubmed:
20
5
2021
medline:
10
8
2021
entrez:
19
5
2021
Statut:
ppublish
Résumé
Enteropathy-associated T cell lymphoma (EATL) is a rare subtype of mature T cell lymphoma. The available literature about this rare type T cell lymphoma is relatively limited. This article provides a summary and review of the available literature addressing this entity in terms of risk factors, pathogenesis, diagnostic, and therapeutic options. EATL has two distinct subtypes. Type I EATL, now known as EATL, is closely, but not exclusively linked to celiac disease (CD), and it is primarily a disease of Northern European origin. It accounts for < 5% of peripheral T cell lymphoma (PTCL). Risk factors for EATL include advanced age, male sex, and most importantly, genetic susceptibility in the form of HLA-DQ2 homozygosity. The pathogenesis of EATL is closely related to celiac disease as it shares common pathogenic features with refractory celiac disease. The gold standard of diagnosis is histological diagnosis. EATL carries an aggressive course and a poor prognosis. Treatment of EATL includes surgery, induction chemotherapy, and consolidation in first complete remission and autologous stem cell transplant. The role of targeted and biologic therapies in newly diagnosed EATL patients along with relapsed, refractory cases is evolving and discussed in this review. EATL is an aggressive peripheral T cell lymphoma with poor overall treatment outcome using currently available therapy options. Clinical trials are considered the best approach for treatment of EATL. Early diagnosis and early referral to specialized centers would be the best way to deal with such patients. Development of new prognostic models and early surgical intervention are warranted. Prevention is where all the efforts should be spent, by counseling patients with CD regarding the importance of adherence to gluten-free diet and development of periodic surveillance programs in celiac disease patients for early detection of pre-lymphoma lesions.
Identifiants
pubmed: 34009525
doi: 10.1007/s11899-021-00634-4
pii: 10.1007/s11899-021-00634-4
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
140-147Références
Wd T, et al. World Health Organization Classification of Tumours This book and all other volumes of the series can be purchased: from all countries. World Health Organization; 2017.
Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118:148–55.
pubmed: 21566094
Vose J. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.
pubmed: 18626005
Malamut G, Chandesris O, Verkarre V, Meresse B, Callens C, Macintyre E, et al. Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45:377–84.
pubmed: 23313469
pmcid: 7185558
Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664–70.
pubmed: 20197551
Verbeek WHM, van de Water JMW, al-Toma A, Oudejans JJ, Mulder CJJ, Coupé VMH. Incidence of enteropathy - associated T-cell lymphoma: A nation-wide study of a population-based registry in The Netherlands. Scand J Gastroenterol. 2008;43:1322–8.
pubmed: 18618372
Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single Center. J Clin Oncol. 2000;18:795–803.
pubmed: 10673521
Corrao G, Corazza GR, Bagnardi V, Brusco G, Ciacci C, Cottone M, et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet. 2001;358:356–61.
pubmed: 11502314
Askling J, Linet M, Gridley G, Halstensen TS, Ekström K, Ekbom A. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology. 2002;123(5):1428–35.
pubmed: 12404215
Cottone M, Termini A, Oliva L, Magliocco A, Marrone C, Orlando A, et al. Mortality and causes of death in celiac disease in a Mediterranean area. Dig Dis Sci. 1999;44:2538–41.
pubmed: 10630509
Gao Y, Kristinsson SY, Goldin LR, Björkholm M, Caporaso NE, Landgren O. Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology. 2009;136:91–8.
pubmed: 18950631
Al-Toma A, Verbeek WHM, Hadithi M, von Blomberg BME, Mulder CJJ. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut. 2007;56:1373–8.
pubmed: 17470479
pmcid: 2000250
Olén O, Askling J, Ludvigsson JF, Hildebrand H, Ekbom A, Smedby KE. Coeliac disease characteristics, compliance to a gluten free diet and risk of lymphoma by subtype. Dig Liver Dis. 2011;43:862–8.
pubmed: 21880561
Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease--effect of a gluten free diet. Gut. 1989;30:333–8.
pubmed: 2707633
pmcid: 1378455
Nijeboer P, de Baaij LR, Visser O, Witte BI, Cillessen SAGM, Mulder CJ, et al. Treatment response in enteropathy associated T-cell lymphoma: survival in a large multicenter cohort. Am J Hematol. 2015;90:493–8.
pubmed: 25716069
Hujoel IA, Murray JA. Refractory celiac disease. Curr Gastroenterol Rep. 2020;22:18.
pubmed: 32185560
van Wanrooij RLJ, et al. Novel variant of EATL evolving from mucosal γδ-T-cells in a patient with type I RCD. BMJ Open Gastroenterol. 2015;2:e000026.
pubmed: 26462278
pmcid: 4599158
Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. Immunol Rev. 2014;260:221–34.
pubmed: 24942692
pmcid: 4066219
Bauer S, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (80- ). 1999;285:727–9.
Wu J, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science (80- ). 1999;285:730–2.
Chander U, Leeman-Neill RJ, Bhagat G. Pathogenesis of enteropathy-associated T cell lymphoma. Curr Hematol Malig Rep. 2018;13:308–17.
pubmed: 29943210
Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, et al. NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study. Gut. 2019;68:1396–405.
pubmed: 30448772
Verbeek WHM, Goerres MS, von Blomberg BME, Oudejans JJ, Scholten PET, Hadithi M, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in Refractory Celiac Disease. Clin Immunol. 2008;126:48–56.
pubmed: 18024205
Verkarre V, Asnafi V, Lecomte T, Patey Mariaud-de Serre N, Leborgne M, Grosdidier E, et al. Refractory coeliac sprue is a diffuse gastrointestinal disease. Gut. 2003;52:205–11.
pubmed: 12524401
pmcid: 1774980
Pastré J, Juvin K, Malamut G, Derrieux C, Cellier C, Israël-Biet D. Phenotypically aberrant clonal T cells in the lungs of patients with type II refractory celiac disease. Blood. 2014;123:3674–5.
pubmed: 24904104
Mention J-J, Ben Ahmed M, Bègue B, Barbe U, Verkarre V, Asnafi V, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology. 2003;125:730–45.
pubmed: 12949719
Malamut G, Afchain P, Verkarre V, Lecomte T, Amiot A, Damotte D, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology. 2009;136:81–90.
pubmed: 19014942
Baumgärtner AK, Zettl A, Chott A, Ott G, Müller-Hermelink HK, Starostik P. High frequency of genetic aberrations in enteropathy-type T-cell lymphoma. Lab Investig. 2003;83:1509–16.
pubmed: 14563952
deLeeuw RJ, et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology. 2007;132:1902–11.
pubmed: 17484883
Zettl A, Ott G, Makulik A, Katzenberger T, Starostik P, Eichler T, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol. 2002;161:1635–45.
pubmed: 12414511
pmcid: 1850794
Moffitt AB, Ondrejka SL, McKinney M, Rempel RE, Goodlad JR, Teh CH, et al. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J Exp Med. 2017;214:1371–86.
pubmed: 28424246
pmcid: 5413324
Leonard JN, Tucker WF, Fry JS, Coulter CA, Boylston AW, McMinn RM, et al. Increased incidence of malignancy in dermatitis herpetiformis. Br Med J (Clin Res Ed). 1983;286:16–8.
Sigurgeirsson B, Agnarsson BA, Lindelöf B. Risk of lymphoma in patients with dermatitis herpetiformis. BMJ. 1994;308:13–5.
pubmed: 8298344
pmcid: 2539155
Branchi F, et al. Enteroscopy and radiology for the management of celiac disease complications: time for a pragmatic roadmap. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2016;48:578–86.
Elli L, et al. Use of enteroscopy for the detection of malignant and premalignant lesions of the small bowel in complicated celiac disease: a meta-analysis. Gastrointest Endosc. 2017;86:264–273.e1.
pubmed: 28433612
Hadithi M, Mallant M, Oudejans J, van Waesberghe J, Mulder CJ, Comans EF. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med. 2006;47:1622–7.
pubmed: 17015897
Hoffmann M, Vogelsang H, Kletter K, Zettinig G, Chott A, Raderer M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut. 2003;52:347–51.
pubmed: 12584214
pmcid: 1773540
Di Sabatino A, Biagi F, Gobbi PG, Corazza GR. How I treat enteropathy-associated T-cell lymphoma. Blood. 2012;119:2458–68.
pubmed: 22271451
Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 1994;5:397–400.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:3059–68.
Shipp MA. International non-Hodgkin’s lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.
de Baaij LR, Berkhof J, van de Water JMW, Sieniawski MK, Radersma M, Verbeek WHM, et al. A new and validated clinical prognostic model (EPI) for enteropathy-associated T-cell lymphoma. Clin Cancer Res an Off J Am Assoc Cancer Res. 2015;21:3013–9.
Nijeboer P, Malamut G, Mulder CJ, Cerf-Bensussan N, Sibon D, Bouma G, et al. Enteropathy-associated T-cell lymphoma: improving treatment strategies. Dig Dis. 2015;33:231–5.
pubmed: 25925928
Wierdsma NJ, Nijeboer P, de van der Schueren MAE, Berkenpas M, van Bodegraven AA, Mulder CJJ. Refractory celiac disease and EATL patients show severe malnutrition and malabsorption at diagnosis. Clin Nutr. 2016;35:685–91.
pubmed: 25979847
Jantunen E, Boumendil A, Finel H, Luan JJ, Johnson P, Rambaldi A, et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood. 2013;121:2529–32.
pubmed: 23361910
d’Amore F, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:3093–9.
Daum S, Ullrich R, Heise W, Dederke B, Foss HD, Stein H, et al. Intestinal non-Hodgkin’s lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin’s Lymphoma. J Clin Oncol. 2003;21:2740–6.
pubmed: 12860953
Sieniawski MK, Lennard AL. Enteropathy-associated T-cell lymphoma: epidemiology, clinical features, and current treatment strategies. Curr Hematol Malig Rep. 2011;6:231–40.
pubmed: 21912848
van de Water JMW, et al. Surgery in (pre)malignant celiac disease. World J Gastroenterol. 2015;21:12403–9.
pubmed: 26604647
pmcid: 4649123
Novakovic BJ, Novakovic S, Frkovic-Grazio S. A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin’s lymphomas. Oncol Rep. 2006;16:191–5.
pubmed: 16786145
Wöhrer S, Chott A, Drach J, Püspök A, Hejna M, Hoffmann M, et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. 2004:1680–3. https://doi.org/10.1093/annonc/mdh427 .
Kim YA, Byun JM, Park K, Bae GH, Lee D, Kim DS, et al. Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. Blood Adv. 2017;1:2138–46.
pubmed: 29296861
pmcid: 5737133
Horwitz S, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229–40.
pubmed: 30522922
Binder C, et al. CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. Ann Hematol. 2013;92:1521–8.
pubmed: 23978945
pmcid: 3790248
Mehta-Shah N, et al. Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis. Blood. 2017;130:4597.
Egan LJ, et al. Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol. 1995;21:123–9.
pubmed: 8583077
Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, et al. Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study(). Leuk Lymphoma. 2017;58:2319–27.
pubmed: 28504033
Park B-B, Kim WS, Suh C, Shin DY, Kim JA, Kim HG, et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol. 2015;94:1845–51.
pubmed: 26251158
Foster C, Kuruvilla J. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. F1000Research. 2020;9.
Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:1970–6.
Vicari AP, Schoepfer AM, Meresse B, Goffin L, Léger O, Josserand S, et al. Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis. MAbs. 2017;9:927–44.
pubmed: 28581883
pmcid: 5540113
Cellier C, et al. 616 - AMG 714 (Anti-IL-15 MAB) Halts the progression of aberrant intraepithelial lymphocytes in refractory celiac disease type II (RCD-II): a phase 2A, randomized, double-blind, placebo-controlled study evaluating AMG 714 in adult patients with RCD-II/Pre. Gastroenterology. 2018;154:S-129–30.
Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M. Novel immunotherapies for T cell lymphoma and leukemia. Curr Hematol Malig Rep. 2018;13:494–506.
pubmed: 30317410
pmcid: 6295363
Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, et al. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131:888–98.
pubmed: 29233821
pmcid: 5824337
Broccoli A, Zinzani PL. Phosphatidyl-inositol 3-kinase inhibitors in the treatment of T-cell lymphomas. Ann Lymphoma. 2018;2(1).